TI
TERN

Trexquant Investment’s Terns Pharmaceuticals TERN Stock Holding History

Trexquant Investment’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,049
Closed -$6.06M – 2048
2025
Q4 		$6.06M Buy
150,049
+111,826
+293% +$2.58M 0.05% 506
2025
Q3 		$287K Buy
+38,223
New +$244K ﹤0.01% 1435
2025
Q2 		– Sell
-139,609
Closed -$385K – 1875
2025
Q1 		$385K Sell
139,609
-113,638
-45% -$464K ﹤0.01% 1342
2024
Q4 		$1.4M Sell
253,247
-50,669
-17% -$343K 0.02% 995
2024
Q3 		$2.53M Buy
303,916
+270,193
+801% +$2.22M 0.03% 718
2024
Q2 		$230K Buy
+33,723
New +$204K ﹤0.01% 1423
2023
Q4 		– Sell
-31,695
Closed -$159K – 1783
2023
Q3 		$159K Sell
31,695
-22,206
-41% -$141K ﹤0.01% 1366
2023
Q2 		$472K Buy
+53,901
New +$628K 0.01% 1030

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Trexquant Investment's TERN Position: Q1 2026 in Review

Trexquant Investment sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 150,049 shares — an estimated $6.06M sold.

Trexquant Investment first reported a position in TERN in Q2 2023 and held it in 8 quarters. The position peaked at $6.06M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Trexquant Investment reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Trexquant Investment sold 150,049 Terns Pharmaceuticals shares in Q1 2026, an estimated $6.06M.
  • Trexquant Investment first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Trexquant Investment's Terns Pharmaceuticals position peaked at $6.06M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.